Compare Immunovant Inc. Common Stock (IMVT) vs MasterCard Inc (MA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Immunovant Inc. Common Stock vs MasterCard Inc — how do they compare? Immunovant Inc. Common Stock trades at $30.01 (market cap $6.62B), while MasterCard Inc trades at $574.4 (market cap $499.38B). The key difference: MasterCard Inc is far larger — about 75.4× Immunovant Inc. Common Stock's market cap, and MasterCard Inc pays a 0.61% dividend while Immunovant Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Immunovant Inc. Common Stock for 0 Days and MasterCard Inc for 134 Days on average.
| IMVT | MA | |
|---|---|---|
Market Cap | $6.62B | $499.38B |
Volume | 1,131,364 | 1,862,680 |
Sector | Health | Financials |
52-Week High | $44.96 | $599.86 |
52-Week Low | $17.03 | $471.55 |
Typical Hold Time | 0 Days | 134 Days |
Enterprise Value | $5.72B | $512.41B |
Dividend Yield | — | 0.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Mastercard (MA) trades at $570.06, up 0.61% with a bullish technical signal and strong institutional interest. The company demonstrates robust fundamentals with 2025 revenue of $32.79B and net income of $14.97B, maintaining exceptional profitability margins. Recent earnings have consistently beaten expectations, with Q2 2026 EPS of $5.04 surpassing the $4.77 estimate. Analyst consensus remains strongly positive with 80% buy ratings and a $666.67 price target, representing 17% upside potential from current levels.
Mastercard presents a compelling growth opportunity with expanding digital payments adoption and strong execution, though faces risks from payment industry disruption and competitive threats. The stock's premium valuation (P/E 31.36) reflects high growth expectations that must be sustained. Near-term catalysts include Q3 2026 earnings and continued AI payment innovation, while regulatory scrutiny and economic sensitivity remain key monitoring points for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Immunovant Inc. Common Stock
Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →About MasterCard Inc
Mastercard Incorporated provides financial transaction processing services. The Company offers payment processing services for credit and debit cards, electronic cash, automated teller machines, and travelers checks. Mastercard serves customers worldwide.
Read more on MA →
